| 영문 | cell-mediated immunity | 한글 | 세포매개면역 |
|---|---|---|---|
| 설명 | 면역이란 신체를 외부의 물질로부터 보호하는 행위를 말한다. 여기에는 특이적 면역과 비특이적 면역의 두 가지가 있다. 비특이적 면역이라함은 특정한 물질에 관계하는 면역이 아니라 특정 대상이 없이 모든 외부 물체에 작용할 수 있는 면역을 말한다. 여기에는 소변의 흐름, 눈물의 흐름, 피부의 비투과성 등의 기계적인 것도 포함되고 피속에 돌아다니는 세포 중에서 비특이적으로 외부의 물질을 포식하는 세포들(예를 들면 큰포식세포(macrophage)의 활동도 포함이 된다. 세포매개면역이란 특이한 물질을 감지할 수 있는 세포를 생성하게 하여 그것으로 하여금 그 물질을 포식하게 하는 것을 말한다. |
||
| 영문 | nerve cell | 한글 | 신경세포 |
|---|---|---|---|
| 설명 | 신경세포는 올바른 신경전달을 위한 각 부분별로 나뉘어져 있다. 신경세포에서는 전해져오는 자극을 전기적인 신호로 바뀌어 보내거나 받게 된다. 이런 전기적인 현상은 각 신경세포내에 존재하는 각 이온채널(ion channel: ion이란 나트륨, 칼륨 등을 지칭하는 말들로써, 이들이 세포막에 의해 나뉘어질 때 생기는 전압차가 전기적 자극을 일으키고 유지하는데 결정적인 역할을 한다)들의 작용에 의해 이루어지게 된다. |
||
| 영문 | glia cell | 한글 | 아교세포 |
|---|---|---|---|
| 설명 | 신경세포 사이에서 그물구조를 이루며 이를 지지하는 조직. 신경아교세포는 신경모세포와 갈라진 아교모세포가 다시 여러 형태로 분화-성장한 것이다. 뇌실이나 척수중심관의 벽을 덮고 원주상 또는 입방형이며, 초기에는 유리면에 섬모가 있다. 대형세포는 별뇌실막세포는 아교세포라고 하며, 신경세포나 신경섬유 사이에 산재한다. 그 외에 희소돌기아교세포도 포함된다. |
||
| 영문 | reserve cell | 한글 | 예비세포 |
|---|---|---|---|
| 설명 | 일반적으로 상피조직에서 이미 있던 상피세포가 손상을 받아 사멸하면 매꿔지는 그 밑에 있는 미분화세포 예를 들면, 기관지 내표면을 덮는 중층 원주 상피의 기저에 있는 작은 미분화 상피 세포. |
||
| 영문 | stem cell | 한글 | 줄기세포, 간세포 |
|---|---|---|---|
| 설명 | 자기 복제를 하여 자신을 존속시키면서 한편으로는 증식과 분화를 하여 새로운 세포를 형성하는 세포로서 조혈줄기세포가 대표적이다. 조혈줄기세포는 골수에 있는 세포로서 모든 혈구세포가 여기에서 분화되어 발생한다. |
||
| SLE | Systemic Lupus Erythematosus; 전신성 홍반성 루푸스(낭창)(全身性 紅斑性) |
|---|---|
| CDLE | chronic discoid lupus erythematosus |
| DIL, Dil | Dilantin; drug-induced lupus [erythematosus] |
| DILE | drug-induced lupus erythematosus |
| LED | light-emitting diode; lowest emitting dose; lupus erythematosus disseminatus |
| pemphigus erythematosus | An eruption involving sun-exposed skin, especially the face; the lesions are scaling erythematous macules and blebs, combining the clinical features of both lupus erythematosus and pemphigus vulgaris; bullae are subcorneal; probably a variant of pemphigus foliaceus. Synonym: Senear-Usher disease, Senear-Usher syndrome. (05 Mar 2000) |
|---|---|
| chilblain lupus | Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains. Synonym: chilblain lupus. (05 Mar 2000) |
| neonatal lupus | Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life. (05 Mar 2000) |
| drug-induced lupus | <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug. Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine. The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare. Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections. (18 Jul 2002) |
| lupus | A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis. (27 Sep 1997) |
| lupus anticoagulant | An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus. (27 Sep 1997) |
| lupus anticoagulants | Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT). Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area. See also cardiolipin antibodies and phospholipid antibodies. (05 Mar 2000) |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |
| lupus erythematodes | Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus. (18 Nov 1997) |
| lupus glomerulonephritis-pathology | Patient survival and preservation of renal function are predictable from renal pathology as demonstrated by biopsy and defined by the histological classification of the International Study of Kidney Disease in Children/World Health Organization (ISKDC/WHO). Semi-quantitative indices of nephron loss (chronicity index) and activity of acute potentially reversible inflammation (activity index) are not predictive of individual outcome, renal failure or death in patients with aggressively treated SLE GN. (05 Mar 2000) |
| lupus-like syndrome | <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause. (05 Mar 2000) |
| lupus livido | Persistent cyanotic lesions on the extremities, associated with the cutaneous manifestations of Raynaud's disease. (05 Mar 2000) |
| lupus lymphaticus | A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles. Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex. (05 Mar 2000) |
| lupus miliaris disseminatus faciei | A millet-like papular eruption of the face, associated with a (histopathologically) tuberculoid perifollicular infiltration, but probably related to rosacea rather than tuberculous infection. (05 Mar 2000) |
| lupus mutilans | Cutaneous tuberculosis with extensive destruction of tissue. (05 Mar 2000) |